Last reviewed · How we verify
HUYABIO International, LLC. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo in combination with nivolumab | Placebo in combination with nivolumab | phase 3 | PD-1 inhibitor | PD-1 | Oncology | |
| HBI-8000 in combination with nivolumab | HBI-8000 in combination with nivolumab | phase 3 | HDAC inhibitor (in combination with PD-1 inhibitor) | Histone deacetylase (HDAC); combined with PD-1 | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ASLAN Pharmaceuticals · 1 shared drug class
- ATGC Co., Ltd. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Akeso · 1 shared drug class
- Amgen · 1 shared drug class
- Asahi Kasei Pharma Corporation · 1 shared drug class
- 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for HUYABIO International, LLC.:
- HUYABIO International, LLC. pipeline updates — RSS
- HUYABIO International, LLC. pipeline updates — Atom
- HUYABIO International, LLC. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). HUYABIO International, LLC. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/huyabio-international-llc. Accessed 2026-05-16.